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Abstract
Existing technologies allow isolating antigen-specific monoclonal antibodies (mAbs) from B cells. We devised a direct
approach to isolate mAbs with predetermined conformational epitope specificity, using epitope mimetics (mimotopes) that
reflect the three-dimensional structure of given antigen subdomains. We performed differential biopanning using
bacteriophages encoding random peptide libraries and polyclonal antibodies (Abs) that had been affinity-purified with
either native or denatured antigen. This strategy yielded conformational mimotopes. We then generated mimotope-
fluorescent protein fusions, which were used as baits to isolate single memory B cells from rhesus monkeys (RMs). To
amplify RM immunoglobulin variable regions, we developed RM-specific PCR primers and generated chimeric simian-
human mAbs with predicted epitope specificity. We established proof-of-concept of our strategy by isolating mAbs
targeting the conformational V3 loop crown of HIV Env; the new mAbs cross-neutralized viruses of different clades. The
novel technology allows isolating mAbs from RMs or other hosts given experimental immunogens or infectious agents.
Citation: Sholukh AM, Mukhtar MM, Humbert M, Essono SS, Watkins JD, et al. (2012) Isolation of Monoclonal Antibodies with Predetermined Conformational
Epitope Specificity. PLoS ONE 7(6): e38943. doi:10.1371/journal.pone.0038943
Editor: Shan Lu, University of Massachusetts Medical Center, United States of America
Received January 20, 2012; Accepted May 14, 2012; Published June 21, 2012
Copyright:  2012 Sholukh et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by NIH grants P01 AI048240, P01 AI048240-08s1, R37 AI034266, and P30 AI060354. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts. The Dana-Farber Cancer Institute has applied for patent
coverage of the new technology: US Patent Application number PCT/US2010/046353 for ‘‘Mimotopes of HIV and Uses Thereof’’ was filed on 8/23/2010 in which
AMS, MH and RMR are listed as co-inventors; a patent application for ‘‘Two Sets of Primers Suitable for Amplification of Rhesus Monkey Immunoglobulin’s Light
and Heavy Chain Variable Domains and Constant Regions’’ listing RMR, AMS, MMM and SSE will be filed shortly. Dana-Farber Cancer Institute requires its
employees to assign patent and other intellectual property rights to the Institute; therefore the co-inventors have no competing financial interests to declare, and
the authors affirm that their adherence to all the PLoS ONE policies on sharing data and materials is unaffected.
* E-mail: ruth_ruprecht@dfci.harvard.edu.
. These authors contributed equally to this work.
Introduction
Isolation of naturally induced and matured antibodies (Abs) is
of prime importance for analytical vaccinology [1,2]. Three
major strategies have been used to interrogate the B-cell
repertoire: traditional phage display, high-throughput screening
of immortalized B cell or plasma cell cultures, and isolation of
antigen-specific B cells to PCR amplify the variable heavy (VH)
and variable light (VL) immunoglobulin (Ig) genes [2,3].
Development and refinement of high-throughput screening
methods, flow cytometric capabilities and single-cell cloning
techniques led to substitution of the traditional phage display
techniques by approaches that allow the isolation of naturally
selected Igs. Phage display is constrained by the diversity of the
library used, by physical-chemical properties of the Ig fragments
displayed and involves random combination of VH/VL pairs.
Consequently, it is not known whether Abs isolated by phage
display represent natural molecules generated by the host in
response to immunization or infection by a pathogen of interest.
Even the recently published technique based upon high-
throughput DNA sequencing of the plasma cell Ig repertoire
with subsequent comprehensive analysis of VH and VL
representation resulting in the assembly of VH/VL pairs left
the possibility that the recovered pair may be artificial [4].
Naturally occurring Abs can be isolated via high-throughput
screening of immortalized memory B or plasma cell cultures. This
approach yielded broad and potent neutralizing monoclonal Abs
(nmAbs) against HIV, dengue and influenza viruses that signifi-
cantly improved our understanding of the specificity and
mechanisms of humoral immunity [5–8]. Isolation of antigen-
specific B cells by sorting with a fluorescence-activated flow
cytometer (FACSorting), first reported in 1972 [9], has led to the
recovery of a number of naturally induced and matured Abs
against rotavirus and HIV [10–12]. However, using the whole
antigen for B-cell sorting implies a need for extensive screening of
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sophisticated approach consists of directly isolating B cells specific
for individual epitopes. The success of this approach depends on
the identification of epitope mimetics (mimotopes) that correctly
reflect the three-dimensional structure of a given antigen
subdomain/epitope. Here we report the development of a novel
methodology using fluorescently labeled mimotopes as baits to
isolate rhesus monkey (RM) memory B cells for subsequent cloning
of Ab genes.
Results
Overview of Strategy
The overall strategy is depicted in Figure 1. Mimotopes were
isolated by biopanning using recombinant bacteriophages encod-
ing random peptide libraries. To enrich for conformational
mimotopes, we devised a new strategy of differential biopanning
that involved positive selection with Abs pre-purified on native
antigen followed by negative selection with Abs eluted from
denatured antigen (Figure 2). After a total of three rounds of
positive/negative selections with these Ab preparations, the
resulting mimotopes are expected to show preferential conforma-
tion dependence. Next, mimotope sequences are cloned into a
vector encoding a fluorescent reporter gene, giving rise to a
fluorescent fusion protein (Figure 1). The latter is used for
mimotope-specific isolation of single memory B cells by flow
cytometry. Single-cell RT-PCR is then used to amplify the VH and
VL Ig genes using newly designed, RM-specific primers. Next, the
VH and VL sequences are cloned into expression vectors encoding
the backbone of human IgG1 heavy or light chains, respectively.
Cotransfection into eukaryotic cells grown in serum-free medium,
will yield recombinant, chimeric simian-human monoclonal Abs
(mAbs). Such mAbs will specifically recognize not only the
fluorescently labeled mimotope fusion protein used for the
selection procedure, but also the corresponding antigen, with the
epitope specificity determined by the nature of the mimotope used
for the selection.
Isolation of Conformational Mimotopes
To validate our new strategy, we sought to isolate mAbs specific
for the V3 loop of the HIV envelope glycoprotein, using
conformation-dependent mimotopes. The V3 loop is a prime
target for nAbs and has conserved structural features in the crown,
although the entire loop structure is known for its remarkable
sequence variability [13]. Anti-V3 mAbs isolated and character-
ized by others [14–17] allowed us to compare and validate the
technology presented here.
We used RMs that had developed high-titer, broadly
neutralizing Abs (nAbs) during chronic infection with simian-
human immunodeficiency virus (SHIV) (Table S1 and Table
S2) for B-cell isolation. First, we affinity-purified polyclonal Abs
that contained paratopes specific for conformational epitopes on
the original antigen molecule. In parallel, we also affinity-
purified polyclonal Abs recognizing the same antigen in
denatured form. Towards this end (Figure 2), wells of 96-well
plates were coated with HIV gp160 under native or denaturing
conditions and incubated with serum of monkey RKl-8. Bound
Abs were eluted by pH shift, identical fractions were combined,
concentrated and used for biopanning of random peptide phage
libraries. ‘‘Conformational’’ Abs (eluted from native, multimeric
gp160, shown in blue, Figure 2) were used for positive selection;
‘‘linear’’ Abs (eluted from denatured gp160, shown in green,
Figure 2) for negative selection. Three positive/two negative
rounds yielded mimotopes that were tested for gp160 specificity
and conformational dependence with RM sera. Interestingly,
only 12 mimotopes resembling the V3 loop crown of HIV
gp120 (Figure 3A) were selected using this method of differential
biopanning with Abs specific for either native or denatured
gp160. Some of these conformational V3 mimotopes were
chosen to test the feasibility of our overall strategy. Notably, our
differential biopanning strategy resulted in the selection of
mimotopes with strong conformational dependence as shown by
ELISA performed with native or denatured phages and probed
with serum from RM RKl-8 (Figure 3B). The fact that only V3-
like mimotopes were found may be ascribed to the stringent
selection conditions. It should be noted that mimotopes
positively selected by the ‘‘conformational’’ Abs (shown in blue,
Figure 2) are discarded in the subsequent negative selection step
if they are also bound to ‘‘linear’’ Abs (shown in green,
Figure 2). As a consequence, the only mimotopes that remain
are those with high specificity and selective binding to the
‘‘conformational’’ Abs, a condition fulfilled by the sterically
constrained V3 loop.
Next, we cloned, bacterially expressed and purified mWasabi-
mimotope fusion proteins (termed mWasabi-mimes, Figure S1).
We analyzed the latter by ELISA with sera from animals with
high-titer nAbs to confirm specificity and cross-recognition.
Mimotope Tc.2 was recognized by serum of different RMs and
serum of monkey RJa-9 demonstrated the highest binding
(Figure 3C). This mimotope closely resembles the V3 loop crown
in amino acid sequence (Figure 3A). Conformational similarity of
mimotope and V3 loop is demonstrated by molecular modeling
and structural superimposition shown on Figure 3D. Noteworthy,
Tc.2 was isolated from cyclic 7mer peptide library and is flanked
by two cysteines forming disulfide bridge thus stabilizing the
mimotope structure.
Isolation of Single Memory B Cells
The cross-reactivity of mimotope Tc.2 with sera from different
RMs implied mimicry of a conserved HIV Env epitope by Tc.2.
Consequently, we selected the corresponding mWasabi-Tc.2
fusion protein as bait to isolate cognate memory B cells from
PBMC of monkey RJa-9 by flow cytometry. Mimotope-specific
single memory B cells were sorted into a PCR plate as follows:
CD3
2/CD19
+/CD27
+/IgG
+/mWasabi-mime
+ (Figure 4). For
the experiment 5610
7 PBMC were used and the cytometer was
programmed to collect 90 individual CD3
2/CD19
+/CD27
+/
IgG
+/mWasabi-mime
+ cells at one cell per well in the plate.
Mimotope-specific cells represented approximately 0.1% of the
memory B cells and as many as 8 mimotope-specific IgG-positive
memory B cells were observed per million lymphocytes sorted.
Control staining with mWasabi yielded only one non-specific cell
per million lymphocytes, possibly due to autofluorescence.
Single-cell PCR and mAb Cloning
After cDNA synthesis, light and heavy chain variable Ig genes
were amplified by semi-nested PCR with a set of newly developed
primers specific to RM Ig genes (Table S3). RM IgG-specific
primers published to date do not result in the amplification of VH
and VL genes of all RM subfamilies [18], whereas our new primer
set led to the amplification of all RM VH and VL genes and yielded
frequencies similar to their natural usage rate (Table S4). This
procedure allowed us to derive VH gene fragments in 31 wells and
VL gene fragments in 19 wells, respectively. In 12 wells, both VH
and VL genes were amplified.
Next, we sequenced matching pairs of VH and VL genes
obtained after two rounds of PCR to assess productivity and
gene rearrangement as well as to obtain sequence information
Isolation of Epitope-Specific Antibodies
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amplification of VH/VL pairs with cloning primers, we inserted
the PCR fragments into vectors of the pFUSE2-family that
contain constant region sequences of human Ig light (Igk or
Igl2) or heavy (Igc1) chains. This cloning strategy yielded
chimeric simian-human IgG1 mAbs.
Functional Characterization of mAbs
Out of 12 isolated VH/VL pairs, 11 chimeric mAbs were
expressed and purified. Two of them, 33B2 and 33C6, exhibited
specific binding to the Tc.2 mimotope and HIV-1CN54 gp120
(Figure S2) as well as HIV envelopes of different clades by ELISA
(Figure 5A, Figure S3). The weaker binding of mAbs to Tc.2
compare to gp120 (Figure S2), especially 33B2, can be explained
by the fact that the mimotope represents only part of entire
epitope due to the relatively short length.
To confirm the expected V3 loop epitope specificity of mAbs
33B2 and 33C6, peptides representing the V3 loop of consensus
HIV clade C gp120 were used for epitope mapping. Peptide
binding analysis revealed a common epitope recognized by both
mAbs (Figure 5B, Figure S4A): the sequence RKSIRIG, which is
located in the V3 loop crown and resembles the epitope of the
known anti-V3 mAb, HGN194 [16]. Interestingly, mAb 33B2
interacted only with peptides 9259 and 9261 bearing the epitope
either at the N- or C-termini but did not bind to peptide 9260,
where the epitope is in the middle, presumably due to improper
conformation of the linear peptide. Peptide 9261 showed the
highest degree of inhibition of mAbs binding to gp120 (Figure S4B
and S4C). Lower binding of mAb 33B2 compared to binding of
33C6 to linear peptides 9260 and 9261 implies that epitope of
33B2 is more conformation-dependent.
Since the mimotope used as B-cell bait was selected to be
strongly conformational, we postulated that 33B2 and 33C6 would
preferentially bind to native as opposed to denatured envelope
proteins. To confirm binding to native Env in trimeric form, we
performed a virion binding assay, in which both mAbs successfully
captured virions of the chimeric simian-human immunodeficiency
virus (SHIV) encoding env of a recently transmitted HIV clade C,
SHIV-1157ipEL-p [19] (Figure 5C). Upon Env denaturation,
binding of both mAbs was strongly diminished by ELISA
(Figure 5D); denaturation greatly abrogated binding of both mAbs
to gp120, whereas reduction of disulfide bridges did not affect
binding.
Next, we assessed potency/breadth of virus neutralization of the
two mAbs with a panel of neutralization-sensitive (tier 1) and more
difficult-to-neutralize (tier 2) viruses. Overall, 33B2 and 33C6
neutralized 75% or 91% of the tier 1 HIV strains of different
clades tested (Table 1), respectively. In contrast, few of the tier 2
strains tested were neutralized by the two new mAbs (7% and
15%, respectively). These results are similar to the neutralization
profiles of other anti-V3 Abs [15–17]. The fact that we preselected
Figure 1. Strategy of isolation of epitope-specific Abs. After differential biopanning of phage display peptide library, mimotopes representing
conformational epitopes are sequenced, and the inserts plus M13 flanking sequences are cloned into a bacterial expression vector encoding
fluorescent protein. After purification of the resulting mimotope fusion proteins, binding assays to assure maintenance of the correct three-
dimensional structure of mimotope insert are conducted. This is followed by single-cell sorting for specific IgG-positive memory B cells, single-cell RT-
PCR and cloning of RM VL and VH regions into pFUSE2-type vectors encoding the backbone of human IgG1.
doi:10.1371/journal.pone.0038943.g001
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finding neutralizing mAbs since most virus-neutralizing Abs are
conformation dependent.
Genetic Analysis of mAbs
Genetic analysis of 33B2 and 33C6 VH and VL genes revealed
that these mAbs likely originated from the same parental B cell
clone, because they share the same VH and JH genes, IGHV5-
51*01 and IGHJ4*2, respectively (Table 2). Although 33B2 and
33C6 used different D genes, the complementarity-determining
region 3 (CDR3) of both mAbs are 16 amino acids long and have
very similar amino acid sequences (Figure 6). In contrast, the light
chains recruited different genes, IGLV1-50 and IGLV1-47, from
the same subfamily (Table 2). The CDR sequence homology
indicates convergence of the molecular evolution of both mAbs
(Figure 6). Our results are in good agreement with data about Ig
gene usage by other anti-V3 Abs [14]. Compared to the RM
germline, the frequency of amino acid mutations observed in VH
was 15% for mAb 33B2 and 18% for 33C6, whereas for VL, the
mutation frequencies were 10% and 15%, respectively (Figure S5
and Figure S6). These values are significantly lower compared to
the recently identified anti-CD4 binding site neutralizing mAbs,
but comparable to the parameters of other anti-V3 mAbs and of
mAb b12 [11,12,16,20–23]. Neither mAb exhibited autoreactivity
in assays involving double-stranded (ds) DNA, Sm, ribonucleo-
protein (RNP), SS-A/Ro and SS-B/La antigens, cardiolipin and
nuclear antigens (data not shown).
Discussion
Our data give proof-of-concept that the novel mAb isolation
strategy, together with the newly developed set of primers specific
to RM Ig genes, yielded mAbs with the epitope specificity as
predicted by the fluorescently labeled mimotope. Our methodol-
ogy represents a direct approach to isolate naturally occurring,
matured Abs as mAbs without the need of extensive screening and
provides a practical tool for analytical vaccinology. In contrast to
other methods of mAb generation using phage display with Ig
fragments that yield randomly recombined Ig chains, isolating
single memory B cells will allow probing of natural Ab repertoires.
Our focus on isolating peripheral blood memory B cells as
preferred source of matured VH/VL genes has an advantage
compared to plasma cells. The latter lack B-cell receptors (BCR),
whereas memory B cells bear antigen receptors recognizing only
one epitope; these receptors serve as targets that are specifically
recognized by fluorescently labeled mimotopes.
An important aspect of our new technology is the use of
conformational mimotopes, which we selected with affinity-
purified polyclonal RM Abs specific for either native or denatured
antigen. We used the power of differential biopanning to select
mimotopes representing conformational epitopes and thus in-
creased the chances of isolating biologically relevant VH/VL genes,
since most Ab paratopes are directed against conformational
targets on the antigen.
Our new approach to isolate conformation-specific mAbs with
predetermined epitope specificity is applicable to any antigen.
Figure 2. Differential biopanning strategy to select conformational mimotopes of desired specificity. HIV gp160 was bound to ELISA
plates under native or denaturing conditions. After incubation with serum of monkey RKl-8 (which was chronically infected with a clade C simian-
human immunodeficiency virus (SHIV) [25] and had high titers of anti-HIV nAbs) followed by washing, Abs were eluted. Abs eluted from the native
protein antigen (‘‘conformational’’ Abs) were used for the positive selection rounds; Abs eluted from the denatured protein (‘‘linear’’ Abs) were used
for the negative rounds. A total of three biopanning rounds were performed and mimotopes selected by this strategy were tested for specificity and
conformation dependence with rhesus monkey sera.
doi:10.1371/journal.pone.0038943.g002
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to isolating HIV envelope-related mAbs. We chose a V3
mimotope to illustrate the power and practicality of our new
approach. By opting to isolate mAbs with a narrow, well
defined epitope specificity, we expect to observe far fewer ‘‘hits’’
when isolating memory B cells compared to standard technol-
ogies using entire antigens as baits. The benefits of our targeted
approach will be that the epitope specificity will be known,
thereby obviating a labor-intensive mapping effort. Another
approach to zero in on a specific antigen region involved an
HIV gp120 that had been redesigned to diminish undesirable
antigenic determinants to facilitate the isolation of B cells
specific for the CD4-binding site [12]. The latter is known to
encompass a number of different epitopes. This approach
required resolving of spatial structure of the antigen as well as
sophisticated protein modeling. In contrast, empirical selection
of epitope mimetics by differential biopanning of phage display
peptide libraries using polyclonal Abs provides a fast and easy
technique to generate mimotopes resembling conformational
epitopes from infected or immunized hosts.
It should be pointed out that our single cell-based mAb
isolation does not depend on using mimotopes with stringent
conformation dependence as baits. In fact, we have performed a
number of RM B-cell isolations with mimotopes that had some
but not exclusive conformation dependence (unpublished data).
In fact, we have performed biopannings with more than 20 RM
sera from vaccinated and/or SHIV-infected animals using
standard rather than differential biopanning. In such cases, we
are generally able to assign the resulting mimotopes to the
corresponding entire antigen of interest in approximately 90%
of the cases based upon partial amino acid similarity. However,
in exceptional cases, as many as 40% to 50% of the mimotopes
could not be assigned and are likely representing quaternary
conformational regions.
Our choice of RMs as source for VH/VL genes will potentially
yield mAbs with clinical applicability as prophylactic or therapeu-
tic agents. Of note, RMs and humans have a closely related
repertoire of Ig genes, much more so than mice, rabbits or other
species used routinely for mAb isolation. Our findings of VH gene
usage, length of CDR3 and frequency of mutations are similar to
anti-V3 Abs derived from HIV-infected individuals, thus confirm-
ing this notion.
Although we demonstrated the ability to generate mAbs with
predetermined epitope specificity using the RM model of
immunodeficiency virus infection, our approach can be readily
extended to any target of choice, such as experimental or natural
infection with potential pathogens, autoimmune diseases and
cancer.
Figure 3. Properties of V3 loop mimotopes. (A) Binding of rhesus monkey RKl-8 serum Abs to native and denatured mimotopes. Wild-type
phages (WT) were used as negative control, an anti-phage Ab (anti-M13 pIII) as positive control to show correct phage immobilization. Each data
point represents the mean 6 s.e.m. (n =3). *Mimotope selected for B-cell sorting. (B) Sequence alignment of V3 loop region of gp160 and
mimotopes isolated by differential biopanning. Amino acid colors indicate: blue, basic; green, non-polar (hydrophobic); orange, polar (uncharged);
magenta (acidic). (C) Binding of RM sera to different V3 mimotopes. Plates were coated with mWasabi-mimotope fusion proteins and parental
mWasabi as control and then probed with sera of rhesus monkeys with high nAb titers. Serum from monkey RKl-8 served as positive control; serum
from a naı ¨ve animal was used as negative control in all experiments. Each data point represents the mean 6 s.e.m. (n =3). (D) Structural
superimposition of Tc.2 mimotope and V3 peptide obtained by in silico molecular modeling. Tc.2 mimotope was modeled using the published V3
peptide structure in complex with Fab2557 [13]. The original V3 loop is shown in blue, the Tc.2 mimotope in orange. The cysteine residues and
disulfide bridge are in green.
doi:10.1371/journal.pone.0038943.g003
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Animals
The current in vitro study only used blood samples from
animals listed in Table S1. These RMs, chronically infected
with clade C SHIV, were part of our ongoing study to establish
and optimize a model to test experimental vaccine approaches
against the most frequent clade of HIV worldwide, and data
from each of these animals have been published previously
[19,24–27]. Animal experiments were carried out in strict
accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the U.S. Public Health
Services/National Institutes of Health, as well as according to
the recommendations in the Weatherall report on ‘‘The Use of
Non-human Primates in Research’’ (http://www.acmedsci.ac.
uk/images/project/nhpdownl.pdf). The protocol was approved
by the Committee on the Ethics of Animal Experiments of
Emory University (IACUC ID: YER-2001401-111814; Emory
University Animal Welfare Assurance Number A3180-01). The
rhesus monkeys were housed at the Yerkes National Primate
Research Center (YNPRC, Emory University, Atlanta, GA).
The animals were housed indoors with a 12 hour light/dark
cycle, in individual cages but in visual and auditory contact with
other RMs, were fed monkey chow (Purina) ad libitum
supplemented daily with fresh fruit. Standard enrichment was
provided by the YNPRC enrichment staff including perches,
rubber toys and varied treats such as peanuts and cereals. Blood
was collected under ketamine or Telazol anesthesia from the
femoral vein. YNPRC facilities are fully accredited by the
Association for Assessment and Accreditation of Laboratory
Figure 4. Isolation of single V3 loop-specific memory B cells by FACSorting. Mimotope-specific memory B cells were selected by the
following phenotype: CD3
2/CD19
+/CD27
+/IgG
+/mWasabi-mimotope
+ and were sorted into individual wells of a 96-well PCR plate. The consecutive
number of gates is shown in the left upper corner of each gate.
doi:10.1371/journal.pone.0038943.g004
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by the Institutional Animal Care and Use Committees at Emory
and the Dana-Farber Cancer Institute via a Collaborating
Institution Animal Use Agreement. Because the experiments
described here involved a virus that may cause an incurable
disease, such as AIDS, discomfort, stress and pain may occur.
Animals were closely monitored and observed for development
of disease at least twice daily. Animals determined to be under
stress or in discomfort, were administered appropriate anesthet-
ics and/or analgesics as directed by the clinical veterinary staff.
If stress cannot be alleviated, the animals are euthanized.
Collection of Human PBMC
This study made use of anonymous human blood donor samples
for in vitro neutralization tests. These cells were derived from the
blood bank at Brigham and Women’s Hospital (Boston, MA),
where leukocytes were collected in Trima collars during platelet
pheresis. The donors were prescreened and found to be negative
for blood-borne pathogens, including HIV-1, hepatitis, and others.
The use of Trima-collar derived PBMC for in vitro neutralization
assays was reviewed by the IRB; this use of human PBMC was
considered to be exempt.
Envelope Proteins and Peptides
HIV envelope proteins of strains UG37, BaL, IIIB, CN54 and
UG21 along with consensus clade C peptides were kindly provided
by the NIH AIDS Research and Reference Reagent Program
(ARRRP). SHIV-1157ip and SIVmne envelope proteins were
generated by recombinant vaccinia virus technology [28].
Differential Biopanning
Affinity purification of polyclonal Abs specific for native
vs. denatured antigens. Affinity purification was performed in
96-well plates coated overnight with HIV gp160SHIV-1157ip under
native or denaturing conditions. On the next day, plates were
washed, blocked and incubated overnight with plasma of monkey
RKl-8. The following day, plates were extensively washed, and
bound Abs were eluted by pH shift. Identical fractions were
combined, concentrated and used for biopanning of random
peptide phage libraries.
Figure 5. Properties of mAbs 33B2 and 33C6. (A) Binding to envelope proteins of different HIV clades. Plates were coated with Env proteins and
probed with newly isolated mAbs along with isotype controls (positive control, HGN194 [16]; negative control, Fm-6 [37]) and cognate rhesus
monkey (RJa-9) serum. HIV Env proteins were derived from the following strains: clade A, UG37; B, BaL and IIIB; C, CN54 and 1157ip (the latter is a
simian-human immunodeficiency virus (SHIV) strain encoding an HIV clade C envelope [25]; D, UG21. SIVmne gp160 was used as negative control. (B)
Epitope mapping. Bars show Ab binding by ELISA to consensus HIV clade C peptides representing the V3 loop region. The control peptide represents
the scrambled C-terminal sequence of SHIV-1157ip gp120. (C) Virion binding assay. MAbs 33B2 and 33C6 along with negative control (Fm-6) and
positive control (HGN194) were captured on the plate coated with goat anti-human IgG Fc-specific Ab and then exposed to SHIV-1157ipEL-p [19]
virions. The amount of virus bound to mAbs was assessed by p27 Gag ELISA. (D) Binding of mAbs 33B2 and 33C6 with native and denatured HIVCN54
gp120. Plates were coated with native, reduced or reduced/denatured HIV Env protein and probed with 33B2 and 33C6 along with Fm-6 (negative
control mAb) as well as serum of HIV-positive individual (positive control), and serum of HIV-negative individual (negative control). We used tris(2-
carboxyethyl)phosphine (TCEP) to reduce gp120 and TCEP + SDS to reduce and denature, respectively (Methods). Each data point represents the
mean 6 s.e.m. (n =3). Experiments were repeated 3 times.
doi:10.1371/journal.pone.0038943.g005
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libraries with polyclonal clade C SHIV-infected RM serum is
described elsewhere [29]. Briefly, paramagnetic beads (Dynabeads
M-280 tosyl-activated; Invitrogen) were coated with rabbit anti-
monkey IgG (Sigma-Aldrich) and pre-incubated with serum Abs
affinity-purified using native gp160SHIV-1157ip (positive selection).
After an overnight incubation with 10 ml of the original phage
display peptide libraries (7mer, cyclic 7mer, 12mer; New England
Biolabs), beads were intensively washed and bound phages were
eluted by a 10 min pH shift using 0.2 M glycine-HCl pH 2.2
supplemented with 1 mg/ml BSA (Sigma-Aldrich) and subse-
quently neutralized with 1 M Tris-HCl pH 9.1 (Sigma-Aldrich).
Eluted phages were used for negative selection with serum Abs
that had been affinity-purified with denatured gp160SHIV-1157ip
(boiled for 3 min in carbonate buffer (pH 9.6) containing 0.05 M
TCEP, tris(2-carboxyethyl)phosphine (Pierce) and 2% SDS (Sig-
ma-Aldrich). Phages remaining in the supernatant after negative
selection were amplified for 4.5 h in E. coli (ER2738, New England
Biolabs), precipitated overnight at 4uC (20% PEG-8000/2.5 M
NaCl; Fisher Scientific), collected, precipitated a second time and
subjected to two more positive/one more negative selection
rounds. Eluted phages from the third positive selection were
titered on LB plates and single clones were picked and tested by
phage ELISA for specific binding. Single-stranded DNA of
positive clones was isolated and sequenced to deduce the
sequences of the peptide inserts, which were grouped into motifs
and assigned to sequences of the Env-C protein, where possible.
Molecular Modeling and Structure Images
Protein modeling and energy calculations were performed using
Discovery Studio (Accelrys Software, Inc.) based on a sequence
alignment of the V3-mimotope with the core structure corre-
sponding to the X-ray structure of ZAM18 V3 peptide in complex
with Fab2557 [13] (pdb code 3MLU). Energies were calculated
using CHARMM (Chemistry at Harvard Macromolecular Me-
chanics). We introduced solvent factors using the implicit of
distance-dependent dielectrics model and performed energy
minimization of the mimotope (Steepest Descent following by
Conjugate Gradient).
Molecular graphics image for antibody [30] (pdb code 1IGT)
was produced using the UCSF Chimera package from the
Resource for Biocomputing, Visualization, and Informatics at
the University of California, San Francisco (supported by NIH
P41 RR001081). Model for mWasabi was generated by Swiss-
Model Workspace [31] (Swiss Institute of Bioinformatics & the
Biozentrum University of Basel) and the image was produced with
UCSF Chimera package.
Table 1. Neutralization activity of mAbs 33B2 and 33C6.
33B2 33C6
Virus Clade Tier IC50 (mg/ml) IC50 (mg/ml)
SHIV strains (M7-Luc assay)
SHIV-KNH1144p A 2 .20 .20
SHIVSF162.P4 B 1 3.98 0.02
SHIV-1157ipEL-p C 1 0.05 0.06
SHIV-1157ipd3N4 C 2 ND .20
SHIV-2873Nip C 2 .20 .20
HIV strains (TZM-bl assay)
Q23.17 A 1 .20 .25
Q259.d2.17 A 2 .20 .25
Q769.d22 A 2 .20 .25
92UG029 A/X4 1/2 ND 0.02
SF162.LS B 1 0.3 0.05
BaL B 1 .20* 0.06*
MN.3 B 1 0.02 ,0.01
BX08 B 1 ND 0.76
6535.3 B 2 .20 .25
RHPA B 2 (.20) (1.2)
SC22.3C2 B 2 (.20) (.25)
QH0692.42 B 2 .20 .25
MW965.26 C 1 ,0.01 ,0.01
92BR025.9 C 1 0.9 0.6
GS015 C 1 ND 0.05
Ce1086_B2 C 2 (17.9) (.25)
Du151.2 C 2 (.20) (.25)
Du156.12 C 2 .20 .25
CAP45.2.00.G3 C 2 .20 .25
Indie-C1 C 2 .20* .25*
20635-4 C 2 ND 13.0
E0836M4 D 2 ND .50
R2184.c04 AE 2 (.20) (.25)
CM235-2 AE 2 (.20) (.25)
CM235 AE 2 ND 27.26
55815 AG 2 ND .50
overall tier 1 neutralization 75% 91%
overall tier 2 neutralization 7% 15%
Neutralization assays were performed in M7-Luc cells (for SHIVs) or TZM-bl cells
(for HIVs) [33] unless otherwise mentioned; values in brackets show
neutralization assays with A3R5.7 cells [36]. *Indicates HIV neutralization in M7-
Luc assay. SHIV, simian-human immunodeficiency virus. ND, not determined.
doi:10.1371/journal.pone.0038943.t001
Figure 6. VH and VL CDR sequences of V3-specific mAbs. (A)
33B2 and 33C6 VH CDR amino acid sequences. (B) 33B2 and 33C6 VL
CDR amino acid sequences.
doi:10.1371/journal.pone.0038943.g006
Table 2. Genetic characteristics of V3-specific mAbs.
Heavy chain genes Light chain genes
mAb VH DH JH Vk/Vl Jk/Jl k/l
33B2 IGHV5-51*01 IGHD3-22*01 IGHJ4*02 IGLV1-50*01 IGLJ3*01 l
33C6 IGHV5-51*01 IGHD5-12*01 IGHJ4*02 IGLV1-47*02 IGLJ3*02 l
doi:10.1371/journal.pone.0038943.t002
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mWasabi-mimotope Fusion Expression (Figure S1)
First, sequences encoding mWasabi with a N-terminal His6-tag
were amplified from the parental plasmid pNCS-mWasabi (Allele
Biotechnology) with primers to introduce NdeI and EcoRI
restriction sites (Table S5) and cloned into the pET-22b(+) vector
(Novagen). The resulting plasmid was termed pET-mWasabi.II.
Next, mimotopes plus flanking regions were amplified from phage
DNA with primers to introduce EcoRI and HindIII restriction
sites (Table S5) followed by cloning into pET-mWasabi.II at the
C-terminus of the fluorescent protein. The mWasabi-mimotope
fusion proteins were expressed in BL21 E.coli and purified on the
Ni
2+-agarose according to the manufacturer instruction.
ELISAs
Phage binding ELISA and mimotope fusion protein ELISA
were performed as published [29].
ELISAs with cell culture supernatants and purified
mAbs. ELISA plates were coated with 50–100 ng/well of
antigens (mimotope fusion proteins, HIV proteins or V3 loop
consensus peptides) in carbonate buffer, pH 9.6. After washing,
plates were blocked with 2% bovine serum albumin (BSA) (Sigma-
Aldrich), 0.05% Tween-PBS (blocking buffer). Plates were then
incubated with cell supernatants diluted with blocking buffer or
purified mAbs diluted at 1 mg/ml with several consecutive 1:4
dilutions in blocking buffer. After washing, the plates were
developed by incubation for 1 h with goat HRP-conjugated anti-
human IgG (Jackson ImmunoResearch) and by adding 100 mlo fo-
phenylenediamine or TMB solution. Optical densities were
measured at the appropriate wavelength using an ELISA
microplate reader (Mithras LB 940, Berthold Technologies).
‘‘Denatured’’ ELISA. Wells of 96-well plates were coated
with gp160SHIV-1157ip under native or denaturing conditions. For
denaturation, antigen was diluted to at 0.5 mg/ml into carbonate
buffer (pH 9.6) containing 0.05 M TCEP and 2% SDS and boiled
for 3 min. Antigen in coating buffer served as ‘‘native’’.
Subsequent ELISAs were performed similarly as described above.
Competitive ELISA. The interaction of anti-V3 loop mAbs
with solid-phase HIVCN54 gp120 was inhibited by peptides
corresponding to the V3 loop of consensus clade C gp120
sequence (Figure S4A). A negative peptide control consisted of a
scrambled C-terminal gp120 peptide (24 amino acids long;
synthesized by the Molecular Biology Core Facilities, DFCI).
Primer Design
To design primers specific for RM Ig genes (Table S3), we
analyzed RM Ig V gene sequences obtained in our group as well
as sequences available through public databases, IMGT, the
international ImMunoGeneTics information systemH (IMGT/
LIGM-DB) and NCBI, The National Center for Biotechnology
Information. Sequence analysis and germline gene identification
were performed using the IMGT-V-Quest software; sequence
alignment was done with DNAStar Lasergene software package
(DNAStar Inc). In addition, using known sequences of rare human
V genes, the RM genome was blasted to identify potential
counterparts. To validate newly designed primers, VH and VL
genes were amplified using cDNA derived from mRNA isolated
from the mixture of bone marrow B cells of 10 RMs. The resulting
PCR products were cloned into the sequencing plasmid vector,
pCR4-TOPO (Invitrogen), and sequenced. Sequences of 300
randomly chosen clones were analyzed.
Mimotope-specific Memory B-cell Isolation
RM PBMC were obtained from YNPRC by overnight shipping
in BD VacutainerH CPT
TM Cell Preparation Tubes (Beckton
Dickinson, BD). Upon arrival, cells were washed with RPMI 1640
(Invitrogen) supplemented with 15% fetal calf serum (FCS)
(Sigma-Aldrich) followed by PBS containing 0.2% BSA (Sigma-
Aldrich). Then, cells were incubated with APC-Cy
TM7 mouse
anti-human CD3 (BD Pharmingen), APC mouse anti-human
CD27 (BD Pharmingen), PE-Cy
TM7 mouse anti-human IgG (BD
Pharmingen), anti-CD19-R-Phycoerythrin (Beckman Coulter) and
mWasabi-mimotope fusion protein for 30 min on ice in PBS-BSA.
Controls were performed with isotype controls and mWasabi.
Cells were then washed twice with ice cold PBS-BSA and single-
cell sorted (FACSAria II (BD Biosciences)) into 96-well PCR plates
as described [32]. Live single-cell sorting of RM mimotope-specific
memory B cells under appropriate biocontainment was available
through the Harvard CFAR Core facility. Plates were snap frozen
on dry ice immediately after the completion of sorting.
Single B-cell RT-PCR and Expression Vector Cloning
cDNA synthesis and Ig amplification were performed as
previously described [32], with following modifications. The
frozen plates with single memory B cells were thawed, and reverse
transcription was performed by adding 3 ml of random hexamer
primers (Applied Biosystems) at 50 mM, 1 ml of 10 mM dNTP mix
(Invitrogen), 0.0625 ml of Igepal CA-630 (Sigma), 40 units of
RNaseOUT
TM (Invitrogen), 1.25 ml of 0.1 DTT (Invitrogen) and
0.25 ml of SuperScript III (Invitrogen) into each well. Reaction
conditions for reverse transcription were as follows: 42uC for
10 min, 25uC for 10 min, 50uC for 60 min and 94uC for 5 min.
The cDNA plates were stored at 220uC until further use. The
IgH, Igl and Igk V genes were amplified independently by semi-
nested PCR starting from 3 ml of cDNA as a template. All PCRs
were performed in 96-well PCR plates in a total volume of 50 ml
containing water, 5 mlo f1 0 6buffer, 1 ml of dNTP mix, each at
10 mM, 1 ml of MgCl2 at 25 mM (Qiagen), by 1 ml of forward
primer mix and reverse primer (Table S3) at 10 mM, and 0.4 mlo f
HotStart Taq DNA polymerase (Qiagen). The PCR thermocycler
program was: 95uC for 15 min; 50 cycles (95uC for 30 sec, 50uC
for Igk and Igl or 54uC for IgH for 30 sec and 72uC for 1 min);
72uC for 10 min. For PCR2, 3 ml of PCR1 product were used as a
template. Forward primers were as in PCR1 and reverse primer
specific for PCR2 (Table S3). Fifty cycles were used with the same
parameters as those for the first round, with annealing temper-
ature of 52uC for Igk and Igl and 57uC for IgH for 30 sec. After
PCR2, the fragments for matching heavy/light chain pairs were
isolated and subjected to direct sequencing with the reverse PCR2
primer. PCR products that represented productive IgH, Igl or Igk
rearranged sequences were reamplified from PCR1 using ‘‘clon-
ing’’ primers. These primers contained unique restriction digest
sites, a Kozak motif, leader peptide coding region and sequences
complementary to FR1. After amplification, DNA fragments were
gel purified, digested and cloned into pFUSE2-CLIg-hk, pFUSE2-
CLIg-hl2 and pFUSE2-CHIg-hG1 (all from Invivogen) containing
the backbones of human Igc1, Igk and Igl, respectively, thus
giving rise to chimeric simian-human mAbs.
Ab Production and Purification
Full-length IgG1 mAbs were produced by transient cotransfec-
tion of the paired heavy and light chain pFUSE plasmids into 293-
F cells (Invitrogen) grown in serum-free FreeStyle
TM 293
Expression Medium (GibcoH Invitrogen) using the TransIT-
PRO
TM Transfection Kit (Mirus Bio). Cells were cultivated for
3 days at 37uC/8% CO2 with continuous shaking at 135 rpm.
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supplemented with Halt Protease Inhibitor Cocktail (Thermo
Fisher) and 1006 penicillin-streptomycin solution (GibcoH In-
vitrogen). Next, supernatants were tested for binding to HIV Env
and mimotopes, and positive mAbs were affinity-purified using
Protein A agarose (GE Healthcare) according to manufacturer’s
instructions. IgG concentrations were determined by measuring
absorbance at 280 nm on Nanodrop 1000 (Thermo Scientific)
using the IgG default protocol.
Virion Binding Assay
ELISA plates (Nunc) were coated with 5 mg/ml of goat anti-
human IgG Fc specific Ab (Jackson ImmunoResearch) overnight
at 4uC. After blocking and washing, mAbs were added at 5 mg/ml
and incubated for 2 h. The plates were washed, SHIV-1157ipEL-
p was added to the mAbs and incubated for 20 h, after which the
plates were washed again and incubated with 0.5% Triton X-100
for 1 h to release p27 from the virus bound to the various mAbs.
The amount of p27 released was determined using a p27 SIV
capture kit (ABL, Inc).
Neutralization Assays
The TZM-bl and M7-Luc assays were performed as described
elsewhere [33] and the human PBMC assay was performed as
reported [34].
A3R5 cell assay. A3R5 (A3.01/R5.6) cells are derived from
the CEM human lymphoblastoid cell line A3.01 [35] and
engineered to express CCR5 (McLinden RJ, Chenine AL,
LaBranche C, Perfetto S, Ochsenbauer C, Kappes J, Montefiori,
DC, Kim JH. ‘‘Novel CD4+/CCR5+/CXCR4+ human T-cell
line shows enhanced sensitivity of HIV-1 to neutralization by
sCD4, mAbs and HIV-1-positive sera’’, manuscript in prepara-
tion); cells were obtained from Drs. Jerome Kim and Robert
McLinden at the US Medical HIV Research Program. The A3R5
assay was performed with Env.IMC.LucR viruses [36]. Neutral-
ization titers reflect the sample concentration at which relative
luminescence units (RLU) were reduced by 50% compared to
RLU in virus control wells after subtraction of background activity
in cell control wells.
Reactivity with Autoantigens
Autoreactivity was tested with an anti-dsDNA EIA kit, anti-Sm/
RNP EIA kit, anti-Sm EIA kit, autoimmune EIA anti-SS-A/Ro
Test, autoimmune EIA anti-SS-B/La test, Bio-Rad Kallestad
ANA screen (all Bio-Rad) and QUANTA LiteH ACA IgG III
(INOVA Diagnostics). Assays were performed on automated PhD
System (Bio-Rad) and DSX
TM System (Dynex Technologies).
Supporting Information
Figure S1 Cloning of mimotopes into the mWasabi
backbone. mWasabi and mimotope fragments were amplified
using specific primers to introduce appropriate restriction sites to
insert both sequences (boxed) into the pET-22b(+) vector.
mWasabi was cloned first and the resulting vector pET-
mWasabi.II served as an acceptor of different mimotopes. After
transformation of E.coli with the resulting plasmids, mWasabi-
mimotope fusion proteins were expressed under IPTG induction
and purified from bacterial cell lysates by metal-affinity chroma-
tography. pNCS-mWasabi was obtained from Allele Biotech.
(TIF)
Figure S2 Binding analysis of 12 293F cell supernatants
to mimotope fusion proteins, mWasabi-Tc.2 and HIV
Env. Supernatants of 293F cells transfected with plasmids
encoding cognate heavy and light immunoglobulin chains were
collected 72 h post-transfection, diluted with blocking buffer
(Material and Methods) and incubated with mWasabi-Tc.2,
mWasabi or HIVCN54 gp120. The anti-V3 loop mAb HGN194
[16] and monkey RJa-9 serum were used as positive controls.
Supernatant from non-transfected 293F cells (0 sup.) served as
negative control. Each data point represents the mean 6 s.e.m. (n
=3).
(TIF)
Figure S3 Binding of mAbs 33B2 and 33C6 to HIV Env of
different clades. Plates were coated with envelope proteins and
probed with different dilutions of mAbs 33B2 and 33C6. HIV Env
proteins were derived from the following strains: clade A, UG37;
B, BaL and IIIB; C, CN54 and 1157ip; D, UG21. SIVmne gp160
was used as negative control. MAb HGN194 served as positive
and Fm-6 [37] as negative isotype controls, respectively. Each data
point represents the mean 6 s.e.m. (n =3).
(TIF)
Figure S4 Inhibition of binding of mAbs to HIVCN54
gp120 by consensus clade C peptides representing the
V3 loop region. ELISA plates were coated with gp120 and
exposed to mAbs mixed with V3 loop peptides (9258, 9259, 9260,
9261, 9262, and 9263) or control peptide representing the
scrambled C-terminus of HIV gp120. Each data point represents
the mean 6 s.e.m. (n =3). (A) Amino acid sequences of linear
consensus clade C peptide representing the V3 loop of gp120; (B)
inhibition of binding of mAb 33B2; and (C) inhibition of binding
of mAb 33C6.
(TIFF)
Figure S5 Alignment of 33B2 and 33C6 VH with human
(HU-IGHV5-51) and rhesus monkey (RM-IGHV-5-51)
germline amino acid sequences and calculation of
mutation frequency versus rhesus monkey germline.
Red amino acids, divergence from the rhesus monkey germline;
green, divergence from the human germline.
(DOC)
Figure S6 Alignment of 33B2 and 33C6 VL with human
(HU-IGLV1-50 and HU-IGLV1-47) and rhesus monkey
(RM-IGLV1-50 and RM-IGLV1-47) germline amino acid
sequences and calculation of mutation frequency versus
rhesus monkey germline. Red amino acids, divergence from
the rhesus monkey germline; green, divergence from the human
germline.
(DOC)
Table S1 Treatment history and clinical parameters for
cohort of RMs used for the study.
(DOC)
Table S2 IC50 neutralization titers of RM sera.
(DOC)
Table S3 Primers for amplification of rhesus monkey
immunoglobulin V heavy and light chain genes.
(DOC)
Table S4 Frequency of RM V gene usage.
(DOC)
Table S5 Primers for amplification of mWasabi and
mimotopes.
(DOC)
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